View Older Stories

May 4, 2026 05:30AM TD Cowen Starts Tonix Pharma (TNXP) at Buy

Apr 15, 2026 07:01AM Tonix publishes TONMYA pharmacokinetics study in peer-reviewed journal

Mar 18, 2026 06:12AM Tonix Pharmaceuticals changes auditor to PricewaterhouseCoopers

Mar 13, 2026 07:52AM Tonix Pharma (TNXP) Misses Q4 EPS by 79c

Mar 5, 2026 04:15PM Tonix publishes pharmacokinetic studies of fibromyalgia drug TONMYA

Mar 3, 2026 06:01AM Tonix Pharmaceuticals moves to NASDAQ Global Select Market

Dec 31, 2025 04:14PM Point72 reports 9.2% passive stake in Tonix Pharma (TNXP)

Dec 16, 2025 07:01AM Tonix licenses TNX-4900 neuropathic pain drug from Rutgers

Nov 17, 2025 07:00AM Tonix launches TONMYA fibromyalgia treatment in US pharmacies

Nov 10, 2025 04:19PM Tonix Pharma (TNXP) Reports In-Line Q3 EPS

Oct 27, 2025 07:02AM Tonix presents fibromyalgia drug data at rheumatology conference

Oct 17, 2025 07:01AM Tonix presents mpox vaccine data at European conference

Oct 14, 2025 07:03AM Tonix presents TNX-1500 data at Japan transplantation congress

Sep 30, 2025 08:35AM Tonix Pharmaceuticals names Ganesh Kamath head of market access

Sep 18, 2025 08:01AM Tonix receives FDA feedback for depression drug development

Sep 17, 2025 07:01AM Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Aug 15, 2025 04:24PM Tonix Pharma (TNXP) gains after market on Tonmya approval

Aug 15, 2025 01:06PM Tonix Pharma (TNXP) halted, news pending

Aug 15, 2025 07:14AM Tonix Pharma (TNXP) Falls as Much as 75%, Pares Decline to Down 17% Amid Jitters Ahead of FDA Decision

Aug 11, 2025 04:17PM Tonix Pharma (TNXP) Tops Q2 EPS by 297c

Jul 10, 2025 07:02AM Tonix presents data on mpox and smallpox vaccine candidate at Vienna congress

Jul 9, 2025 04:01PM Tonix publishes phase 3 fibromyalgia trial results in Pain Medicine

Jul 7, 2025 07:03AM Tonix to present mpox vaccine data at Vienna congress

Jul 2, 2025 07:01AM Tonix Pharma (TNXP) Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

Jun 12, 2025 06:04AM Tonix Pharma (TNXP) Files $500M Mixed Shelf

May 21, 2025 07:00AM Tonix Pharma (TNXP) Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

May 12, 2025 04:37PM Tonix Pharma (TNXP) Tops Q1 EPS by 284c

Apr 24, 2025 07:56AM Tonix Pharma (TNXP) Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

Apr 9, 2025 07:02AM Tonix Pharma (TNXP) and Makana Therapeutics Announce Collaboration Combining TNX-1500 with Makana’s Genetically Engineered Organs

Apr 1, 2025 07:01AM Tonix Pharma (TNXP) Launches TONIX ONE

Mar 31, 2025 07:00AM Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

Mar 29, 2025 08:30AM New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc.

Mar 25, 2025 10:01AM Noble Capital Out Positive on Tonix Pharma (TNXP) Following FDA Update, 'We continue to expect product approval on or before August 15, 2025'

Mar 24, 2025 08:04AM Tonix Pharma (TNXP) Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL

Mar 20, 2025 07:00AM As Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread

Mar 18, 2025 04:58PM Tonix Pharma (TNXP) Misses Q4 EPS by 586c

Mar 12, 2025 07:30AM Tonix’s TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target

Feb 7, 2025 08:33AM Tonix Pharma (TNXP) Reports Prelim FY24 Results

Feb 6, 2025 08:00AM Tonix Pharma (TNXP) Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoim

Feb 4, 2025 07:02AM Tonix Pharma (TNXP) Appoints Siobhan Fogarty as CTO

Feb 3, 2025 08:05AM Tonix Pharma (TNXP) Announces 1:100 Reverse Share Split

Dec 23, 2024 08:01AM Tonix Pharma (TNXP) Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102

Dec 17, 2024 08:02AM Tonix Pharma (TNXP) Announces FDA Acceptance of the NDA for TNX-102

Dec 9, 2024 07:30AM Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers

Nov 14, 2024 07:30AM Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Nov 13, 2024 09:05AM Tonix Pharma (TNXP) Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised A

Nov 12, 2024 08:11AM Tonix Pharma (TNXP) Tops Q3 EPS by 270c

Nov 1, 2024 07:01AM Tonix Pharma (TNXP) Presented Data on Potential Mpox Vaccine TNX-801

Oct 17, 2024 08:03AM Tonix Pharma (TNXP) Receives First Contract Payment from U.S. DoD for Accelerated Development of Broad-Spectrum Antivirals with the DTRA

Oct 16, 2024 08:05AM Tonix Pharma (TNXP) Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration

View Older Stories